Acute Kidney Injury Clinical Trial
— WeCANOfficial title:
Weaning of Renal Replacement Therapy in Critically Ill Patients With Acute Kidney Injury: Predictive Performance of Urinary Parameters
Data on the optimal period for RRT weaning in critically ill patient are scarce. The current practice for RRT weaning is based on urine output, the threshold of which is debatable. Two recent observational studies have shown that an increase in urinary creatinine or urea concentrations is a better predictive marker of RRT weaning than urine output. An unjustified delay in RRT weaning leads to numerous complications such as catheter-related infections, delay of the patient's functional recovery, severe ionic disorder, bleeding, and induced hemodynamic instability. It also induces an increase workload for careers and in cost without any additional benefit for the patient. Conversely, too early weaning inevitably limits the prevention on fluid accumulation that is independently associated with an increased risk of mortality and inevitably leads to resumption of RRT requiring reinsertion of dialysis catheter resulting in potential complications. A multicentre randomized controlled trial will be then necessary and only able to identify the optimal RRT weaning strategy. The main objective is to compare two RRT weaning strategies on RRT duration in critically ill patients with acute kidney injury: a strategy based on combined criteria (urine output + urinary parameters) as compared to a single strategy based only on urine output. The study protocol will be an open-label, two parallel group, multicenter, randomized, controlled clinical trial, in which enrolled ICU adult patients will have RRT weaning based either on urine output alone (single strategy) or on urine output and urinary parameters (combined strategy). When the urine output is greater than 500ml/24h, the enrollment must be performed within 24hours in 2 groups:. " Single strategy ": In the single strategy, RRT weaning will be achieved when urine output exceeds 500ml/24h without diuretics or 2000ml/24h with diuretics use. " Combined strategy": In the combined strategy, when urine output exceeds 500ml/day with or without diuretic use, RRT will be stopped during 48h to assess urinary indices (urinary creatinine and urea). Soon as urinary indices are higher than thresholds values (urinary creatinine > 5.2mmol/day and urinary urea > 1.35mmol/kg/day, RRT will be weaned. If they are lower, a RRT session will be perform after which the weaning process will be resume. The primary endpoint is the number of RRT-free days at D30 with at least 7 consecutive days alive and without RRT.
Status | Not yet recruiting |
Enrollment | 600 |
Est. completion date | December 2025 |
Est. primary completion date | September 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Adults (18 years of age or older) - Admitted to the ICU - Receiving or having received invasive mechanical ventilation and/or catecholamine infusion (epinephrine or norepinephrine or dobutamine) at least 48h - With acute kidney injury, at KDIGO 3 (See Appendix 1) stage and associated with oliguria at least < 200ml/ 24h before RRT initiation - Treated with intermittent or continuous renal replacement therapy - Resumption of urine output > 300ml/24h with or without diuretic use Exclusion Criteria: - Preexisting Chronic kidney disease with estimated glomerular filtration rate (eGFR) < 30ml/min - AKI caused by vascular occlusion, glomerulonephritis, vasculitis, post-renal obstruction, thrombotic microangiopathy, tumor lysis syndrome - RRT for another cause than AKI (eg: drug intoxication,...) - Decision to forgo life-sustaining treatment including RRT - Cirrhosis with Child-Pugh score of C or hepatorenal syndrome - Kidney transplantation - Patient already enrolled in the study - Participation in another clinical trial assessing the impact or duration of RRT - Pregnancy in progress or planned during the study period or breastfeeding women - Patients protected by law (Art. L1121-6 and L1121-8 of the Code de la Santé Publique) : Adult protected by law or patient under guardianship or curatorship - Subjects not covered by public health insurance - Absence of written informed consent from the patient or his or her proxy (if present) before inclusion or when possible when the patient has been included in an emergency setting |
Country | Name | City | State |
---|---|---|---|
France | Clermont-Ferrand Hospital University | Clermont-Ferrand | |
France | Montpellier University Hospital | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of RRT-free days at D30 with at least 7 consecutive days alive and without RRT | Days without RRT | Day30 | |
Secondary | Number of RRT weaned days at Day90 | Days without RRT | Day90 | |
Secondary | Number of RRT sessions in ICU and at Day90 | Days without RRT | in ICU and at Day90 | |
Secondary | Renal recovery at Day30 | Number of patient with a serum creatinine lower than 125% of the baseline serum creatinine | Day30 | |
Secondary | Renal recovery at Day90 | Number of patient with a serum creatinine lower than 125% of the baseline serum creatinine | Day90 | |
Secondary | Serum Creatinine and urea at ICU discharge | Serum creatinine and urea values | Day of ICU discharge | |
Secondary | Serum Creatinine and urea at Day90 | Serum creatinine and urea values | Day90 | |
Secondary | Number of days in ICU and hospital within Day90 | Days | within Day90 | |
Secondary | Rate of ICU, hospital and Day90 mortality | Number of died patients | Day90 | |
Secondary | Costs related to RRT and ICU stay within Day90 | Euros | within Day90 | |
Secondary | Number of RRT resumption between inclusion and Day30 | Number of RRT | between inclusion and Day30 | |
Secondary | Rate of dialysis catheter-related colonization in ICU | Number per patient and number per catherter-days | Day30 | |
Secondary | Rate of dialysis catheter-related infection in ICU | Number per patient and number per catherter-days | Day30 | |
Secondary | Incidence of hypokalemia with and without clinical complications in ICU | Defined as a serum potassium concentration < 3.5 mmol/L | Day30 | |
Secondary | Incidence of hypophosphatemia with and without clinical complications in ICU | Defined as a serum phosphate concentration < 0.6 mmol/L | Day30 | |
Secondary | Incidence of hyponatremia with and without clinical complications in ICU | Defined as a serum sodium concentration < 135 mmol/L | Day30 | |
Secondary | Rate of bleeding and etiologies in ICU | Number per patient | Day30 | |
Secondary | Rate of cardio-vascular events in ICU | Defined as : rhythm disorders (ventricular tachycardia, ventricular fibrillation, episode of atrial fibrillation requiring medical treatment or external electric counter shock), cardiac failure, ischemic events, cardiac arrest, arterial hypotension and hypertension requiring treatment | Day30 | |
Secondary | Rate of severe hypoxemia related to fluid overload | Defined as pulmonary edema requiring oxygen therapy to maintain an SpO2 of more than 95% in ICU | Day30 | |
Secondary | Rate of documented gastric ulcers in ICU | Number per patient | Day30 | |
Secondary | Rate of nosocomial infections in ICU | Number per patient | Day30 | |
Secondary | Nadir of serum bicarbonate in ICU | Serum bicarbonate value | Day30 | |
Secondary | Number of days with mechanical ventilation and high-flow nasal cannula oxygen therapy in ICU | Days | Day30 | |
Secondary | Number of days with vasopressors treatment in ICU | Days | Day30 | |
Secondary | Incidence of hyperkalemia with and without clinical complications in ICU | Defined as a serum potassium concentration > 5 mmol/L | Day30 | |
Secondary | Incidence of hyperphosphatemia with and without clinical complications in ICU | Defined as a serum phosphate concentration > 1.5 mmol/L | Day30 | |
Secondary | Incidence of hypernatremia with and without clinical complications in ICU | Defined as a serum sodium concentration > 145 mmol/L | Day30 |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05538351 -
A Study to Support the Development of the Enhanced Fluid Assessment Tool for Patients With Acute Kidney Injury
|
||
Recruiting |
NCT06027788 -
CTSN Embolic Protection Trial
|
N/A | |
Completed |
NCT03938038 -
Guidance of Ultrasound in Intensive Care to Direct Euvolemia
|
N/A | |
Recruiting |
NCT05805709 -
A Patient-centered Trial of a Process-of-care Intervention in Hospitalized AKI Patients: the COPE-AKI Trial
|
N/A | |
Recruiting |
NCT05318196 -
Molecular Prediction of Development, Progression or Complications of Kidney, Immune or Transplantation-related Diseases
|
||
Recruiting |
NCT05897840 -
Continuous Central Venous Oxygen Saturation Measurement as a Tool to Predict Hemodynamic Instability Related to Renal Replacement Therapy in Critically Ill Patients
|
N/A | |
Recruiting |
NCT04986137 -
Fractional Excretion of Urea for the Differential Diagnosis of Acute Kidney Injury in Cirrhosis
|
||
Terminated |
NCT04293744 -
Acute Kidney Injury After Cardiac Surgery
|
N/A | |
Completed |
NCT04095143 -
Ultrasound Markers of Organ Congestion in Severe Acute Kidney Injury
|
||
Not yet recruiting |
NCT06026592 -
Detection of Plasma DNA of Renal Origin in Kidney Transplant Patients
|
||
Not yet recruiting |
NCT06064305 -
Transcriptional and Proteomic Analysis of Acute Kidney Injury
|
||
Terminated |
NCT03438877 -
Intensive Versus Regular Dosage For PD In AKI.
|
N/A | |
Terminated |
NCT03305549 -
Recovery After Dialysis-Requiring Acute Kidney Injury
|
N/A | |
Completed |
NCT05990660 -
Renal Assist Device (RAD) for Patients With Renal Insufficiency Undergoing Cardiac Surgery
|
N/A | |
Completed |
NCT04062994 -
A Clinical Decision Support Trial to Reduce Intraoperative Hypotension
|
||
Terminated |
NCT02860130 -
Clinical Evaluation of Use of Prismocitrate 18 in Patients Undergoing Acute Continuous Renal Replacement Therapy (CRRT)
|
Phase 3 | |
Completed |
NCT06000098 -
Consol Time and Acute Kidney Injury in Robotic-assisted Prostatectomy
|
||
Not yet recruiting |
NCT05548725 -
Relation Between Acute Kidney Injury and Mineral Bone Disease
|
||
Completed |
NCT02665377 -
Prevention of Akute Kidney Injury, Hearttransplant, ANP
|
Phase 3 | |
Terminated |
NCT03539861 -
Immunomodulatory Biomimetic Device to Treat Myocardial Stunning in End-stage Renal Disease Patients
|
N/A |